DEFA14A: Relmada Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals

Relmada Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 23, 2025, with proposals including the election of a Class I director, ratification of the accounting firm, and an amendment to the equity incentive plan.

Summary

• Relmada Therapeutics, Inc. will hold its Annual Meeting of Stockholders on May 23, 2025.
• Stockholders are invited to vote on several key proposals.
• The proposals include the election of Fabiana Fedeli as Class I director for a three-year term expiring in 2028.
• Another proposal is to ratify the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Additionally, stockholders will vote on an amendment to the Relmada Therapeutics, Inc. 2021 Equity Incentive Plan to increase the available shares by 2.0 million.
• The proxy materials are available online, and stockholders can request a free copy by May 9, 2025.
• Voting can be done online at www.ProxyVote.com or virtually during the meeting.

Sentiment

Score: 7

Explanation: The document is a routine corporate communication, presenting standard proposals for shareholder voting. The sentiment is neutral to slightly positive due to the proactive engagement with shareholders.

Positives

• Stockholders have multiple avenues to access proxy materials and cast their votes, including online and virtual options.
• The proposed increase in shares for the equity incentive plan could attract and retain talent.

Future Outlook

The document outlines the proposals to be voted on at the upcoming annual meeting, which will influence the company's governance and equity structure.

Industry Context

This announcement is a standard part of corporate governance, ensuring shareholders have the opportunity to participate in key decisions regarding the company's direction and oversight.

Stakeholder Impact

• Shareholders can influence the company's direction through their votes.
• Employees may be affected by the equity incentive plan amendment.
• The selection of the accounting firm impacts the credibility of financial reporting.

Next Steps

• Stockholders to review proxy materials and vote on the proposals.
• The company to hold the Annual Meeting on May 23, 2025.
• The company to implement the outcomes of the shareholder votes.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Relmada Therapeutics, Fabiana Fedeli, CBIZ CPAs P.C., Equity Incentive Plan, Voting, Shares